<dd id='elc9h'><tbody id='elc9h'><td id='elc9h'><optgroup id='elc9h'><strong id='elc9h'></strong></optgroup><address id='elc9h'><ul id='elc9h'></ul></address><big id='elc9h'></big></td><table id='elc9h'></table></tbody><pre id='elc9h'></pre></dd><span id='elc9h'><b id='elc9h'></b></span>
<dfn id='elc9h'><optgroup id='elc9h'></optgroup></dfn><tfoot id='elc9h'><bdo id='elc9h'><div id='elc9h'></div><i id='elc9h'><dt id='elc9h'></dt></i></bdo></tfoot>
<ul id='elc9h'></ul>
<fieldset id='elc9h'></fieldset>
YH003是一款人源化CD40抗體(ti)，祐和醫藥(yao)將授權(quan)ISU ABXIS使(shi)用YH003的序(xu)列通過其技術平臺來構建(jian)若干組三特異(yi)性抗體(ti)，用于開發針對多種腫瘤類型的治療性藥(yao)物(wu)。(醫藥(yao)健聞)
<option id='elc9h'></option><select id='elc9h'><span id='elc9h'><form id='elc9h'></form></span><dd id='elc9h'></dd></select><dt id='elc9h'></dt><style id='elc9h'><big id='elc9h'><i id='elc9h'></i><tbody id='elc9h'></tbody></big></style><abbr id='elc9h'></abbr>
